Terns Non Current Liabilities Total from 2010 to 2024
| TERN Stock | USD 5.71 0.11 1.96% |
Non Current Liabilities Total | First Reported 2010-12-31 | Previous Quarter 1.2 M | Current Value 1.1 M | Quarterly Volatility 6.5 M |
Check Terns Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Terns Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 335.7 K, Net Interest Income of 13.5 M or Interest Income of 13.5 M, as well as many indicators such as Price To Sales Ratio of 143, Dividend Yield of 0.0 or PTB Ratio of 1.72. Terns financial statements analysis is a perfect complement when working with Terns Pharmaceuticals Valuation or Volatility modules.
Terns | Non Current Liabilities Total |
Latest Terns Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Terns Pharmaceuticals over the last few years. It is Terns Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Terns Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Terns Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 10,049,380 | |
| Geometric Mean | 6,194,459 | |
| Coefficient Of Variation | 64.78 | |
| Mean Deviation | 5,927,493 | |
| Median | 14,467,000 | |
| Standard Deviation | 6,509,945 | |
| Sample Variance | 42.4T | |
| Range | 13.9M | |
| R-Value | (0.81) | |
| Mean Square Error | 15.5T | |
| R-Squared | 0.66 | |
| Significance | 0.0002 | |
| Slope | (1,183,447) | |
| Total Sum of Squares | 593.3T |
Terns Non Current Liabilities Total History
About Terns Pharmaceuticals Financial Statements
Terns Pharmaceuticals investors utilize fundamental indicators, such as Non Current Liabilities Total, to predict how Terns Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 1.2 M | 1.1 M |
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
Moving against Terns Stock
| 0.65 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.51 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.37 | KTTAW | Pasithea Therapeutics | PairCorr |
| 0.35 | VERA | Vera Therapeutics | PairCorr |
| 0.35 | DVAX | Dynavax Technologies | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Terns Pharmaceuticals Correlation against competitors. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.